Cancer Drug Resistance

<div>A 3D Biomimetic System for Testing Anticancer Drugs Sensitivity.-&nbsp;Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays.-&nbsp;Co-Culture of Two Different Cell Lines in a Two-Layer Microfluidic Device.-&nbsp;Generation and Culture of Organotypic Breast Carcinoma Spheroids for the Study of Drug Response in a 3D Microfluidic Device.-&nbsp;A Methodological Workflow to Analyze Synthetic Lethality and Drug Synergism in Cancer Cells.-&nbsp;Establishment of In Vivo Acquired Resistance to Chemotherapy via Individual Dose Escalation Treatment Regime.-&nbsp;A Label Retaining System to Capture Slow Cycling Cancer Cells.-&nbsp;A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.-&nbsp;Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understand the Complex Tumor Biology.-&nbsp;Analysis of Transcriptomic Data Generated from Drug Treated Cancer Cell Line.-&nbsp;Simultaneous Mapping of Enhancers and Enhancer Rearrangements with Paired-End H3K27ac ChIP-seq.-&nbsp;Identification of Drug Resistance Mechanisms using Genome-Wide CRISPR-Cas9 Screens.-&nbsp;RNA Sequencing Data Analysis on the Maser Platform and the Tag-Count Comparison-Graphical User Interface.-&nbsp;Dissecting the Epigenomic Driving Drug Resistance by ATAC-Seq.-&nbsp;Polygenomic Interrogation of Drug Resistance Genes.-&nbsp;Analysis of ER-phagy in Cancer Drug Resistance.-&nbsp;Drug Target Prediction using Context-Specific Metabolic Models Reconstructed from rFastcormics.</div>